Pelthos Therapeutics Inc. Deferred Costs, Current
Pelthos Therapeutics Inc. (PTHS) had Deferred Costs, Current of $22.02 thousand as of 2023-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Balance Sheet › Assets › Assets, Current › Deferred Costs, Current
us-gaap:DeferredCostsCurrent · last filed 2025-03-27
- 2023-12-31: Deferred Costs, Current $22.02K.
| Period end | Deferred Costs, Current |
|---|---|
| 2023-12-31 | $22.02K 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |